KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Jun 2025 value amounting to $844.2 million.

  • Jazz Pharmaceuticals' Capital Expenditures rose 11804.84% to $844.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $882.1 million, marking a year-over-year increase of 3006.52%. This contributed to the annual value of $38.1 million for FY2024, which is 58.88% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Capital Expenditures of $844.2 million as of Q2 2025, which was up 5,981.49% from $13.9 million recorded in Q1 2025.
  • Jazz Pharmaceuticals' 5-year Capital Expenditures high stood at $844.2 million for Q2 2025, and its period low was -$4.9 million during Q3 2022.
  • For the 3-year period, Jazz Pharmaceuticals' Capital Expenditures averaged around $92.0 million, with its median value being $8.6 million (2023).
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Capital Expenditures tumbled by 158.86% in 2022, and later soared by 11,804.84% in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Capital Expenditures (Quarterly) stood at $10.0 million in 2021, then declined by 5.91% to $9.4 million in 2022, then rose by 7.72% to $10.1 million in 2023, then soared by 31.53% to $13.3 million in 2024, then soared by 11,804.84% to $844.2 million in 2025.
  • Its Capital Expenditures was $844.2 million in Q2 2025, compared to $13.9 million in Q1 2025 and $13.3 million in Q4 2024.